Torrent Pharmaceuticals Ltd. has announced it will acquire a 46.4% stake in JB Chemicals & Pharmaceuticals Ltd. from KKR & Co., a private equity firm.

The deal values JB Pharma at 1,600 rupees (US$18.70) per share, totaling around US$1.4 billion, as said in a release on June 29, 2025.

Following the acquisition, Torrent plans to launch a mandatory open offer to purchase up to 26% of JB Pharma shares at 1,639 rupees (US$19.16) per share.

The company also intends to buy up to 2.80% of shares from select employees at the same price as the KKR transaction.

Additionally, Torrent and JB Pharma are considering a merger through a scheme of arrangement.

🔗 Source: Bloomberg

🧠 Food for thought

1️⃣ Private equity’s pharma investment cycle demonstrates India’s healthcare value creation

KKR’s exit from JB Chemicals with a reported fivefold return in just five years highlights the significant value creation potential in India’s pharmaceutical sector 1.

This transaction follows a pattern of successful private equity investments in Indian pharma companies, where firms acquire businesses, implement operational improvements, and exit at premium valuations.

The JB Chemicals case is particularly noteworthy as KKR purchased its stake from the founding Mody family in 2020 and has now achieved substantial returns despite global economic uncertainties.

During KKR’s ownership period, JB Chemicals expanded its therapeutic offerings into areas like dermatology and cardiology, while also receiving key regulatory approvals, including from the US FDA, enhancing its global market access 2.

This investment cycle highlights how private equity firms contribute to pharmaceutical sector development through capital infusion, governance improvements, and strategic guidance before monetizing their investments.

2️⃣ Indian pharma consolidation accelerates as companies pursue scale advantages

The Torrent-JB Chemicals merger represents a significant step in India’s pharmaceutical consolidation trend, with the combined entity set to become the fifth-largest player in the domestic market 3.

This deal aligns with broader industry patterns where Indian pharmaceutical companies are pursuing scale to enhance competitiveness, with domestic M&A accounting for 72% of all deal volumes in Q1 2025 4.